$AGIO
Agios Pharmaceuticals Inc Stock $agio

$agio Overview Financials Valuation SEC Filings Company Website

2018 Q3 Form 10-Q Financial Statement

#000143922218000014 Filed on August 02, 2018

Income Statement

Concept	2018 Q3	2018 Q2	2017 Q2
Revenue	$15.20M	$40.41M	$11.35M
YoY Change	33.81%	256.2%	62.6%
Cost Of Revenue	$695.0K	$0.00
YoY Change
Gross Profit	$14.50M	$40.41M
YoY Change	27.69%
Gross Profit Margin	95.43%	100.0%
Selling, General & Admin	$31.10M	$26.63M	$16.13M
YoY Change	78.12%	65.1%	27.61%
% of Gross Profit	214.44%	65.89%
Research & Development	$82.56M	$86.73M	$79.82M
YoY Change	13.23%	8.66%	57.11%
% of Gross Profit	569.27%	214.6%
Depreciation & Amortization	$1.800M	$1.800M	$1.600M
YoY Change	12.5%	12.5%	14.29%
% of Gross Profit	12.41%	4.45%
Operating Expenses	$114.4M	$113.4M	$95.95M
YoY Change	26.54%	18.15%	51.22%
Operating Profit	-$99.16M	-$72.95M	-$84.60M
YoY Change	25.49%	-13.77%	49.81%
Interest Expense	$4.500M	$4.200M	$1.520M
YoY Change	139.36%	176.32%	192.31%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$94.66M	-$68.75M	-$83.08M
YoY Change	22.71%	-17.25%	48.49%
Income Tax
% Of Pretax Income
Net Earnings	-$94.66M	-$68.75M	-$83.08M
YoY Change	22.72%	-17.26%	48.49%
Net Earnings / Revenue	-622.87%	-170.1%	-732.26%
Basic Earnings Per Share
Diluted Earnings Per Share	-$1.631M	-$1.191M	-$1.777M
COMMON SHARES
Basic Shares Outstanding	57.99M shares	57.61M shares	48.20M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q3	2018 Q2	2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$669.9M	$716.9M	$586.0M
YoY Change	31.9%	22.34%	25.92%
Cash & Equivalents	$156.5M	$210.3M	$138.7M
Short-Term Investments	$513.4M	$506.6M	$447.3M
Other Short-Term Assets	$16.50M	$15.50M	$13.00M
YoY Change	7.84%	19.23%	46.07%
Inventory	$863.0K
Prepaid Expenses
Receivables	$4.500M	$1.600M
Other Receivables	$3.800M	$19.70M
Total Short-Term Assets	$695.5M	$753.8M	$604.7M
YoY Change	31.65%	24.66%	24.89%
LONG-TERM ASSETS
Property, Plant & Equipment	$24.61M	$24.13M	$24.77M
YoY Change	2.47%	-2.57%	-1.44%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$208.5M	$219.7M	$129.9M
YoY Change	55.83%	69.13%	176.97%
Other Assets	$416.0K	$595.0K	$1.249M
YoY Change	-61.12%	-52.36%	-9.62%
Total Long-Term Assets	$233.5M	$244.5M	$155.9M
YoY Change	46.98%	56.78%	112.3%
TOTAL ASSETS
Total Short-Term Assets	$695.5M	$753.8M	$604.7M
Total Long-Term Assets	$233.5M	$244.5M	$155.9M
Total Assets	$929.1M	$998.2M	$760.6M
YoY Change	35.2%	31.24%	36.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$16.62M	$17.32M	$23.41M
YoY Change	-7.17%	-26.01%	26.89%
Accrued Expenses	$25.30M	$25.79M	$29.64M
YoY Change	-17.74%	-12.98%	105.64%
Deferred Revenue	$42.14M
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$84.75M	$84.87M	$93.65M
YoY Change	-3.82%	-9.37%	39.22%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$84.10M	$90.20M	$158.0M
YoY Change	-43.67%	-42.91%	-21.51%
Total Long-Term Liabilities	$84.10M	$90.20M	$158.0M
YoY Change	-43.67%	-42.91%	-21.51%
TOTAL LIABILITIES
Total Short-Term Liabilities	$84.75M	$84.87M	$93.65M
Total Long-Term Liabilities	$84.10M	$90.20M	$158.0M
Total Liabilities	$168.9M	$175.1M	$251.6M
YoY Change	-28.87%	-30.41%	-6.29%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.013B	-$918.2M	-$632.6M
YoY Change	42.7%	45.13%	73.88%
Common Stock	$1.775B	$1.744B	$1.142B
YoY Change	53.02%	52.65%	75.03%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$760.2M	$823.1M	$509.0M
YoY Change
Total Liabilities & Shareholders Equity	$929.1M	$998.2M	$760.6M
YoY Change	35.2%	31.24%	36.41%

Cashflow Statement

Concept	2018 Q3	2018 Q2	2017 Q2
OPERATING ACTIVITIES
Net Income	-$94.66M	-$68.75M	-$83.08M
YoY Change	22.72%	-17.26%	48.49%
Depreciation, Depletion And Amortization	$1.800M	$1.800M	$1.600M
YoY Change	12.5%	12.5%	14.29%
Cash From Operating Activities	-$63.80M	-$67.40M	-$59.00M
YoY Change	-17.89%	14.24%	-137.39%
INVESTING ACTIVITIES
Capital Expenditures	-$3.100M	-$1.400M	-$1.000M
YoY Change	55.0%	40.0%	-64.29%
Acquisitions
YoY Change
Other Investing Activities	$5.900M	-$94.90M	-$274.6M
YoY Change	-91.37%	-65.44%	-813.25%
Cash From Investing Activities	$2.800M	-$96.30M	-$275.8M
YoY Change	-95.78%	-65.08%	-872.55%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$270.2M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	7.200M	9.500M	273.2M
YoY Change	35.85%	-96.52%	18113.33%
NET CHANGE
Cash From Operating Activities	-63.80M	-67.40M	-59.00M
Cash From Investing Activities	2.800M	-96.30M	-275.8M
Cash From Financing Activities	7.200M	9.500M	273.2M
Net Change In Cash	-53.80M	-154.2M	-61.60M
YoY Change	796.67%	150.32%	-131.59%
FREE CASH FLOW
Cash From Operating Activities	-$63.80M	-$67.40M	-$59.00M
Capital Expenditures	-$3.100M	-$1.400M	-$1.000M
Free Cash Flow	-$60.70M	-$66.00M	-$58.00M
YoY Change	-19.82%	13.79%	-136.11%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018Q2	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	0	USD
	dei	Entity Registrant Name EntityRegistrantName	AGIOS PHARMACEUTICALS INC
	dei	Trading Symbol TradingSymbol	AGIO
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Document Period End Date DocumentPeriodEndDate	2018-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Central Index Key EntityCentralIndexKey	0001439222
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2018Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2018Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2018Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	57932639	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48826153	shares
CY2018Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	57932639	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48826153	shares
CY2017Q2	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	2489000	USD
	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	0	USD
	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	5265000	USD
	dei	Document Type DocumentType	10-Q
CY2018Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	57992576	shares
CY2018Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	210323000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	102724000	USD
CY2018Q2	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	506582000	USD
CY2018Q2	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	506582000	USD
CY2017Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	321212000	USD
CY2018Q2	agio	Collaboration Receivable Duefrom Related Parties Current CollaborationReceivableDuefromRelatedPartiesCurrent	19326000	USD
CY2017Q4	agio	Collaboration Receivable Duefrom Related Parties Current CollaborationReceivableDuefromRelatedPartiesCurrent	2448000	USD
CY2018Q2	agio	Collaboration Receivable Other Current CollaborationReceivableOtherCurrent	440000	USD
CY2017Q4	agio	Collaboration Receivable Other Current CollaborationReceivableOtherCurrent	0	USD
CY2018Q2	agio	Royalty Receivable Duefrom Related Parties Current RoyaltyReceivableDuefromRelatedPartiesCurrent	1573000	USD
CY2017Q4	agio	Royalty Receivable Duefrom Related Parties Current RoyaltyReceivableDuefromRelatedPartiesCurrent	1222000	USD
CY2018Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	15538000	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	17655000	USD
CY2018Q2	us-gaap	Assets Current AssetsCurrent	753782000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	445261000	USD
CY2018Q2	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	219724000	USD
CY2017Q4	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	143814000	USD
CY2018Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	24134000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	24431000	USD
CY2018Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	595000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	891000	USD
CY2018Q2	us-gaap	Assets Assets	998235000	USD
CY2017Q4	us-gaap	Assets Assets	614397000	USD
CY2018Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	17320000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	22767000	USD
CY2018Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	25793000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	34031000	USD
CY2018Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	41132000	USD
CY2017Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	37842000	USD
CY2018Q2	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	625000	USD
CY2017Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	301000	USD
CY2018Q2	us-gaap	Liabilities Current LiabilitiesCurrent	84870000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	94941000	USD
CY2018Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	72408000	USD
CY2017Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	125798000	USD
CY2018Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	17815000	USD
CY2017Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	18155000	USD
CY2018Q2	us-gaap	Liabilities Liabilities	175093000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	238894000	USD
CY2018Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q2	us-gaap	Common Stock Value CommonStockValue	58000	USD
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	49000	USD
CY2018Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1743657000	USD
	agio	Collaboration Revenue Other Revenues CollaborationRevenueOtherRevenues	12440000	USD
	agio	Collaboration Revenue Other Revenues CollaborationRevenueOtherRevenues	0	USD
CY2018Q2	us-gaap	Royalty Revenue RoyaltyRevenue	1573000	USD
CY2017Q2	us-gaap	Royalty Revenue RoyaltyRevenue	0	USD
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1174904000	USD
CY2018Q2	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-2398000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-1389000	USD
CY2018Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-918175000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-798061000	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	823142000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	375503000	USD
CY2018Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	998235000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	614397000	USD
CY2018Q2	agio	Collaboration Revenue Revenue From Related Parties CollaborationRevenueRevenueFromRelatedParties	26401000	USD
CY2017Q2	agio	Collaboration Revenue Revenue From Related Parties CollaborationRevenueRevenueFromRelatedParties	11346000	USD
	agio	Collaboration Revenue Revenue From Related Parties CollaborationRevenueRevenueFromRelatedParties	33746000	USD
	agio	Collaboration Revenue Revenue From Related Parties CollaborationRevenueRevenueFromRelatedParties	21854000	USD
CY2018Q2	agio	Collaboration Revenue Other Revenues CollaborationRevenueOtherRevenues	12440000	USD
CY2017Q2	agio	Collaboration Revenue Other Revenues CollaborationRevenueOtherRevenues	0	USD
	us-gaap	Royalty Revenue RoyaltyRevenue	2990000	USD
	us-gaap	Royalty Revenue RoyaltyRevenue	0	USD
CY2018Q2	us-gaap	Revenues Revenues	40414000	USD
CY2017Q2	us-gaap	Revenues Revenues	11346000	USD
	us-gaap	Revenues Revenues	49176000	USD
	us-gaap	Revenues Revenues	21854000	USD
CY2018Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	86730000	USD
CY2017Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	79816000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	164954000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	142548000	USD
CY2018Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	26633000	USD
CY2017Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16130000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	51183000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	30953000	USD
CY2018Q2	us-gaap	Operating Expenses OperatingExpenses	113363000	USD
CY2017Q2	us-gaap	Operating Expenses OperatingExpenses	95946000	USD
	us-gaap	Operating Expenses OperatingExpenses	216137000	USD
	us-gaap	Operating Expenses OperatingExpenses	173501000	USD
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-72949000	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-84600000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-166961000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-151647000	USD
CY2018Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	4204000	USD
CY2017Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	1518000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	7391000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	2399000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-68745000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-83082000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-159570000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-149248000	USD
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.19
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.78
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.81
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.35
CY2018Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	57721786	shares
CY2017Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	46745760	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	56713795	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	44525478	shares
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-68745000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-83082000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-159570000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-149248000	USD
CY2018Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	245000	USD
CY2017Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-438000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1009000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-337000	USD
CY2018Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-68500000	USD
CY2017Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-83520000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-160579000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-149585000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-159570000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-149248000	USD
	us-gaap	Depreciation Depreciation	3464000	USD
	us-gaap	Depreciation Depreciation	3164000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	30977000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	22921000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1291000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-94000	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	20000	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-40000	USD
	agio	Increase Decrease In Collaboration Receivable Due From Related Parties Current IncreaseDecreaseInCollaborationReceivableDueFromRelatedPartiesCurrent	16878000	USD
	agio	Increase Decrease In Collaboration Receivable Due From Related Parties Current IncreaseDecreaseInCollaborationReceivableDueFromRelatedPartiesCurrent	-44000	USD
	agio	Increase Decrease In Collaboration Receivable Other Current IncreaseDecreaseInCollaborationReceivableOtherCurrent	440000	USD
	agio	Increase Decrease In Collaboration Receivable Other Current IncreaseDecreaseInCollaborationReceivableOtherCurrent	0	USD
	agio	Increase Decreasein Royalty Receivable Duefrom Related Parties Current IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent	351000	USD
	agio	Increase Decreasein Royalty Receivable Duefrom Related Parties Current IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent	0	USD
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	0	USD
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-2638000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2413000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2417000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-6198000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	4930000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-7841000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-2392000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-10644000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-11184000	USD
	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	16000	USD
	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	1653000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-166395000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-133063000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	592664000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	468556000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	331666000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	303711000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2793000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1328000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-263791000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-166173000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	391000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	-104000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	516206000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	270250000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	21970000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	6845000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	537785000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	277199000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	107599000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-22037000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	102724000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	160754000	USD
CY2018Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	210323000	USD
CY2017Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	138717000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1365000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1383000	USD
	agio	Proceeds From Stock Options Exercised In Other Current Assets ProceedsFromStockOptionsExercisedInOtherCurrentAssets	0	USD
	agio	Proceeds From Stock Options Exercised In Other Current Assets ProceedsFromStockOptionsExercisedInOtherCurrentAssets	3000	USD
	agio	Public Offering Costs In Other Current Assets PublicOfferingCostsInOtherCurrentAssets	0	USD
	agio	Public Offering Costs In Other Current Assets PublicOfferingCostsInOtherCurrentAssets	125000	USD
CY2018Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	8152986	shares
CY2018Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	67.00
CY2018Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	516200000	USD
CY2018Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	936600000	USD
CY2018Q1	us-gaap	Deferred Revenue DeferredRevenue	124184000	USD
CY2018Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-758605000	USD
CY2018Q2	agio	Collaboration Receivable Duefrom Related Parties Current CollaborationReceivableDuefromRelatedPartiesCurrent	19326000	USD
CY2018Q2	agio	Collaboration Receivable Other Current CollaborationReceivableOtherCurrent	440000	USD
CY2018Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	41132000	USD
CY2018Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	72408000	USD
CY2018Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-918175000	USD
CY2018Q2	agio	Collaboration Revenue Revenue From Related Parties CollaborationRevenueRevenueFromRelatedParties	26401000	USD
	agio	Collaboration Revenue Revenue From Related Parties CollaborationRevenueRevenueFromRelatedParties	33746000	USD
CY2018Q2	agio	Collaboration Revenue Other Revenues CollaborationRevenueOtherRevenues	12440000	USD
	agio	Collaboration Revenue Other Revenues CollaborationRevenueOtherRevenues	12440000	USD
CY2018Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	86730000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	164954000	USD
CY2018Q2	us-gaap	Operating Expenses OperatingExpenses	113363000	USD
	us-gaap	Operating Expenses OperatingExpenses	216137000	USD
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-72949000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-166961000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-68745000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-159570000	USD
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.19
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.81
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-68745000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-159570000	USD
CY2018Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-68500000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-160579000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-159570000	USD
	agio	Increase Decrease In Collaboration Receivable Due From Related Parties Current IncreaseDecreaseInCollaborationReceivableDueFromRelatedPartiesCurrent	16878000	USD
	agio	Increase Decrease In Collaboration Receivable Other Current IncreaseDecreaseInCollaborationReceivableOtherCurrent	440000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-10644000	USD
CY2017Q2	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0	USD
CY2018Q2	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0	USD
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0	USD
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0	USD
CY2017Q2	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	0	USD
	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	0	USD
CY2018Q2	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	0	USD
	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	0	USD
CY2018Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	728704000	USD
CY2018Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	4000	USD
CY2018Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2402000	USD
CY2018Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	726306000	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	466415000	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1389000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	465026000	USD
	agio	Available For Sale Securities Non Current Minimum Liquidating Period AvailableForSaleSecuritiesNonCurrentMinimumLiquidatingPeriod	P12M
CY2018Q2	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear	246	security
CY2017Q4	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear	240	security
CY2018Q2	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	616500000	USD
CY2017Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	439400000	USD
	us-gaap	Revenue Recognition Multiple Element Arrangements RevenueRecognitionMultipleElementArrangements	<div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">On January 1, 2018 we adopted ASC 606 under the modified retrospective method. Prior to January 1, 2018 we accounted for the Collaboration Agreements under ASC 605-25, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;vertical-align:bottom;">Multiple Element Arrangements.</span></div><div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;vertical-align:bottom;">Accounting under ASC 606</span></div><div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">In adopting ASC 606, we applied the practical expedient that permits aggregating the effect of all modifications that occurred prior to January 1, 2018. No other practical expedients were used. Similar to the accounting under ASC 605-25, the 2016 Agreement was determined to be a modification of the 2010 Agreement and the AG-881 Agreements. In determining the appropriate amount of revenue to be recognized under ASC 606, we performed the following steps: (i) identified the promised goods or services in the contract; (ii) determined whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measured the transaction price, including the constraint on variable consideration; (iv) allocated the transaction price to the performance obligations; and (v) recognized revenue when (or as) we satisfied each performance obligation.</span></div><div style="line-height:120%;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;vertical-align:bottom;">As part of the accounting for these arrangements, we must develop assumptions that require judgment to determine the stand-alone selling price, or SSP, for each performance obligation identified in the contract. We use key assumptions to determine the SSP, which include forecast of revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.</span></div>
CY2018Q2	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	0	USD
	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	0	USD
CY2018Q2	agio	Collaboration Revenue Revenue From Related Parties CollaborationRevenueRevenueFromRelatedParties	26401000	USD
CY2017Q2	agio	Collaboration Revenue Revenue From Related Parties CollaborationRevenueRevenueFromRelatedParties	11346000	USD
	agio	Collaboration Revenue Revenue From Related Parties CollaborationRevenueRevenueFromRelatedParties	33746000	USD
	agio	Collaboration Revenue Revenue From Related Parties CollaborationRevenueRevenueFromRelatedParties	21854000	USD
CY2018Q2	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	0	USD
CY2017Q2	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	2489000	USD
	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	0	USD
	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	5265000	USD
CY2018Q2	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	9932000	USD
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	15917000	USD
CY2018Q2	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	220000	USD
	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	543000	USD
CY2018Q2	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	121800000	USD
CY2018Q2	us-gaap	Royalty Revenue RoyaltyRevenue	1600000	USD
	us-gaap	Royalty Revenue RoyaltyRevenue	3000000.0	USD
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	23.63
CY2018Q2	agio	Revenue Remaining Performance Obligation C Stone Agreement RevenueRemainingPerformanceObligationCStoneAgreement	1300000	USD
CY2018Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	9135000	USD
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	15693000	USD
CY2018Q2	agio	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	14568000	USD
CY2017Q4	agio	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	14849000	USD
CY2018Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1875000	USD
CY2017Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3140000	USD
CY2018Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	215000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	349000	USD
CY2018Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	25793000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	34031000	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5577562	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	49.58
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1224670	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	78.14
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	869272	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	226484	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	75.98
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5706476	shares
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	58.62
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2778508	shares
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	52.30
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	5706476	shares
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	58.62
CY2018Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	16455000	USD
CY2017Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12187000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	30977000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	22921000	USD
CY2018Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	16455000	USD
CY2017Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12187000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	30977000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	22921000	USD
CY2018Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6166573	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6166573	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6203800	shares
CY2017Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6203800	shares

Files In Submission

Name	View Source	Status
0001439222-18-000014-index-headers.html	Edgar Link	pending
0001439222-18-000014-index.html	Edgar Link	pending
0001439222-18-000014.txt	Edgar Link	pending
0001439222-18-000014-xbrl.zip	Edgar Link	pending
agio-20180630.htm	Edgar Link	pending
agio-20180630.xsd	Edgar Link	pending
agio-20180630_cal.xml	Edgar Link	unprocessable
agio-20180630_def.xml	Edgar Link	unprocessable
agio-20180630_htm.xml	Edgar Link	completed
agio-20180630_lab.xml	Edgar Link	unprocessable
agio-20180630_pre.xml	Edgar Link	unprocessable
agiosag-120chinalicens.htm	Edgar Link	pending
exhibit31-1x06x30x2018.htm	Edgar Link	pending
exhibit31-2x06x30x2018.htm	Edgar Link	pending
exhibit32-1x06x30x2018.htm	Edgar Link	pending
exhibit32-2x06x30x2018.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AGIO
Agios Pharmaceuticals Inc Stock $agio

2018 Q3 Form 10-Q Financial Statement

#000143922218000014 Filed on August 02, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AGIO Agios Pharmaceuticals Inc Stock $agio

2018 Q3 Form 10-Q Financial Statement

#000143922218000014 Filed on August 02, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AGIO
Agios Pharmaceuticals Inc Stock $agio